Details for New Drug Application (NDA): 213374
✉ Email this page to a colleague
The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 213374
| Tradename: | DEFERASIROX |
| Applicant: | Alkem Labs Ltd |
| Ingredient: | deferasirox |
| Patents: | 0 |
Suppliers and Packaging for NDA: 213374
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DEFERASIROX | deferasirox | GRANULE;ORAL | 213374 | ANDA | Ascend Laboratories, LLC | 67877-675 | 67877-675-84 | 30 PACKET in 1 CARTON (67877-675-84) / 1 GRANULE in 1 PACKET (67877-675-71) |
| DEFERASIROX | deferasirox | GRANULE;ORAL | 213374 | ANDA | Ascend Laboratories, LLC | 67877-676 | 67877-676-84 | 30 PACKET in 1 CARTON (67877-676-84) / 1 GRANULE in 1 PACKET (67877-676-72) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 90MG | ||||
| Approval Date: | Jul 14, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 180MG | ||||
| Approval Date: | Jul 14, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 360MG | ||||
| Approval Date: | Jul 14, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
